Oral News and Research

RSS

Vaccine given to newborns 60% effective against rotavirus in Ghana

Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana. Rotavirus causes fever, vomiting and diarrhea, which in infants can cause severe dehydration.

18 Jun 2013

Mount Sinai researchers present several new studies at ENDO 2013

Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.

17 Jun 2013

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.

17 Jun 2013

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.

15 Jun 2013

New state-of-the-art SmileBest Dental & Orthodontics office opens in Hurst

Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.

15 Jun 2013

Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet, a delayed-release formulation of generic metformin, at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL.

15 Jun 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

13 Jun 2013

Chemotherapy devices: an interview with Damien Salauze, head of Curie-Cancer

Although several chemotherapy treatments are now administered by the oral route (targeted chemotherapy), most chemotherapy treatments (cytotoxics) are administered by the intravenous route.

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Elevated levels of inflammatory biomarkers in individuals associated with high risk of COPD exacerbations

Simultaneously elevated levels of the biomarkers C-reactive protein, fibrinogen and leukocyte count in individuals with chronic obstructive pulmonary disease (COPD) were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations, according to a study in the June 12 issue of JAMA.

12 Jun 2013

Loyola University surgeon uses electrical stimulation as part of surgical technique to treat Bell's palsy

A Loyola University Medical Center surgeon is using electrical stimulation as part of an advanced surgical technique to treat Bell's palsy. Bell's palsy is a condition that causes paralysis on one side of a patient's face.

12 Jun 2013

Bacterium that causes gum disease delivers one-two punch by triggering protective proteins in oral cavity

The newly discovered bacterium that causes gum disease delivers a one-two punch by also triggering normally protective proteins in the mouth to actually destroy more bone, a University of Michigan study found.

12 Jun 2013

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.

12 Jun 2013

Hebrew University student develops drug formulations to treat illnesses through skin applications

New, more efficient drug formulations designed to treat illnesses through skin applications -- thus avoiding serious side effects associated with oral drug-taking -- have been developed by a student at the Hebrew University of Jerusalem.

12 Jun 2013

Study finds only 5% of US wash hands long enough to kill germs

A new study by Michigan State University researchers found that only 5 percent of people who used the bathroom washed their hands long enough to kill the germs that can cause infections.

11 Jun 2013

New study explores effects of growth hormone on the skin

It seems everyone's talking about human growth hormone these days. CNN, Fox News, The Today Show, The Dr. Oz Show, Shape magazine… even Vanity Fair have all done features on hGH. Many of Hollywood's "elite" have been visiting some of the most expensive clinics in the world for controversial hGH therapy. Why? Because they believe human growth hormone can reduce wrinkles, tighten saggy skin, decrease body fat, increase lean muscle mass, boost energy, rev up sex drive, and make you look and feel decades — not years, but DECADES — younger.

11 Jun 2013

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

ViroPharma Incorporated today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral disease in patients with impaired cell mediated immunity.

11 Jun 2013

Oral News and Research

Vaccine given to newborns 60% effective against rotavirus in Ghana

Mount Sinai researchers present several new studies at ENDO 2013

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

New state-of-the-art SmileBest Dental & Orthodontics office opens in Hurst

Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

Chemotherapy devices: an interview with Damien Salauze, head of Curie-Cancer

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Elevated levels of inflammatory biomarkers in individuals associated with high risk of COPD exacerbations

Loyola University surgeon uses electrical stimulation as part of surgical technique to treat Bell's palsy

Bacterium that causes gum disease delivers one-two punch by triggering protective proteins in oral cavity

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Hebrew University student develops drug formulations to treat illnesses through skin applications

Study finds only 5% of US wash hands long enough to kill germs

New study explores effects of growth hormone on the skin

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News